<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04130802</url>
  </required_header>
  <id_info>
    <org_study_id>DX-216</org_study_id>
    <nct_id>NCT04130802</nct_id>
  </id_info>
  <brief_title>OCS-01 in Treating Inflammation and Pain in Post-cataract Patients</brief_title>
  <acronym>SKYGGN</acronym>
  <official_title>A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of Two Doses of OCS 01 Compared to Vehicle in the Treatment of Inflammation and Pain Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oculis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oculis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study
      evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the
      treatment of inflammation and pain following cataract surgery. The primary objective is to
      evaluate the efficacy and safety of OCS-01 compared to placebo and the secondary objective is
      to evaluate the optimal dosing frequency (once a day [QD] or twice a day [BID]).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-masked, placebo (vehicle)-controlled study,
      designed to evaluate the efficacy and safety of OCS-01 ophthalmic suspension (QD versus BID)
      compared to placebo in treating inflammation and pain following cataract surgery. Subjects
      will be randomized 1:1:1 to receive OCS-01 QD, OCS-01 BID, or placebo BID. Subjects will dose
      1 drop in the study eye BID for 14 days, beginning 1 day post-surgery in the operated eye.
      The study will last up to 24 days, including a follow-up visit at Visit 7 (Day 22 ± 2).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>For masking purposes, each dosing box and the pouches within it will be labeled either &quot;AM&quot; or &quot;PM.&quot; Dosing boxes and pouches will be labeled this way regardless of whether the product within the 2 boxes is the same (i.e. OCS-01 BID and placebo treatment arms) or different (i.e. OCS-01 QD).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior chamber cells</measure>
    <time_frame>at Day 15</time_frame>
    <description>Absence of anterior chamber cells as measured by slit beam with fluoresceine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular pain</measure>
    <time_frame>at Day 4</time_frame>
    <description>Absence of pain as assed by Ocular Pain Grading Scale (Min 0, Max 10) in which 0 is no pain and 10 is the worst possible.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Inflammation Corneal</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>OCS-01 1.5% mg/mL QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCS-01 1.5% mg/mL BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Vehicle) BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL</intervention_name>
    <description>OCS-01 eye drops</description>
    <arm_group_label>OCS-01 1.5% mg/mL BID</arm_group_label>
    <arm_group_label>OCS-01 1.5% mg/mL QD</arm_group_label>
    <other_name>DexNP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle eye drops</description>
    <arm_group_label>OCS-01 1.5% mg/mL QD</arm_group_label>
    <arm_group_label>Placebo (Vehicle) BID</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent, approved by the appropriate ethics committee;

          2. Be able to comply with the study requirements and visit schedule;

          3. Be at least 18 years of age of either sex or any race;

          4. Be planning to undergo unilateral cataract extraction via phacoemulsification and
             PCIOL implantation in the study eye;

          5. Have an anterior chamber cell score ≥ 2 at Visit 2 (Day 1 [18 to 30 hours
             post-uncomplicated cataract surgery without vitreous loss]);

          6. Have a pin-hole visual acuity (VA) without any other correction &gt; 20 letters
             (approximately 20/400) in the operative eye and &gt; 35 letters (approximately 20/200) in
             the fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study
             (ETDRS) chart at Visit 1 (Day -1 to Day -28 [prior to surgery]);

          7. Have a negative urine pregnancy test at Visit 1 (Day -1 to Day -28 [prior to
             surgery]),

        Exclusion Criteria:

          1. Have a known sensitivity or allergy to dexamethasone, corticosteroids, or any of the
             study medication's components;

          2. Be monocular;

          3. Have any intraocular inflammation (e.g. white blood cells or flare) present in either
             eye at the Visit 1 (Day -1 to Day -28 [prior to surgery]) slit lamp examination;

          4. Have a score &gt; 0 on the Ocular Pain Assessment at Visit 1 (Day -1 to Day -28 [prior to
             surgery]) in the study eye;

          5. Use anti-inflammatory agents, analgesics/pain relievers (including opioids, narcotics,
             and other pain medications), or immunomodulating agents, systemically or in either
             eye, and/or use medications for benign prostatic hyperplasia (BPH), from the washout
             period through the duration of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oculis SA</last_name>
    <phone>+41 21 711 3970</phone>
    <email>info@oculis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical cennre</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical center</name>
      <address>
        <city>Roseburg</city>
        <state>Oregon</state>
        <zip>97471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ohira A, Hara K, Jóhannesson G, Tanito M, Ásgrímsdóttir GM, Lund SH, Loftsson T, Stefánsson E. Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema. Acta Ophthalmol. 2015 Nov;93(7):610-5. doi: 10.1111/aos.12803. Epub 2015 Jul 23.</citation>
    <PMID>26201996</PMID>
  </reference>
  <reference>
    <citation>Tanito M, Hara K, Takai Y, Matsuoka Y, Nishimura N, Jansook P, Loftsson T, Stefánsson E, Ohira A. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011 Oct 10;52(11):7944-8. doi: 10.1167/iovs.11-8178.</citation>
    <PMID>21896859</PMID>
  </reference>
  <reference>
    <citation>Jóhannesson G, Moya-Ortega MD, Ásgrímsdóttir GM, Lund SH, Thorsteinsdóttir M, Loftsson T, Stefánsson E. Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid. Acta Ophthalmol. 2014 Sep;92(6):550-6. doi: 10.1111/aos.12334. Epub 2013 Dec 24.</citation>
    <PMID>24373641</PMID>
  </reference>
  <reference>
    <citation>Saari KM, Nelimarkka L, Ahola V, Loftsson T, Stefánsson E. Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation. Graefes Arch Clin Exp Ophthalmol. 2006 May;244(5):620-6. Epub 2005 Oct 11.</citation>
    <PMID>16217662</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post-cataract,</keyword>
  <keyword>inflammation</keyword>
  <keyword>Pain</keyword>
  <keyword>post-surgery</keyword>
  <keyword>corticosteroid</keyword>
  <keyword>anterior chamber cells</keyword>
  <keyword>flares</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Keratitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

